Diverse Leukemia Stem Cells May Drive AML Relapse After Therapy

Diverse leukemia stem cells may drive AML relapse after therapy

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).

Leukemia stem cells cause treatments to fail, but findings open new avenues to overcome resistance

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are not just one, but four different subtypes of leukemia stem cells. This diversity could explain why one of the most important AML drugs does not work sufficiently in some patients or loses its effectiveness over time—resulting in…

Leukemia Stem Cell Diversity Drives Treatment Resistance in AML

Scientists from the German Cancer Research Center and HI-STEM have uncovered a major reason why acute myeloid leukemia (AML) frequently returns after treatment. Their findings, published in Cell Stem Cell, reveal that leukemia stem cells, the rare but critical cells that sustain the disease, exist in multiple biologically distinct forms, each with different vulnerabilities and resistance mechanisms. The discovery helps explain why venetoclax, on…

Leukemia Stem Cells Drive Treatment Failure: New Discoveries Pave Way to

In a groundbreaking study spearheaded by researchers at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), a pivotal mechanism underlying treatment failure in acute myeloid leukemia (AML) has been unraveled. This investigation reveals that AML does not arise from a single type of leukemia stem […]

Leukemia stem cells cause treatments to fail - Findings open new avenues to overcome resistance

Acute myeloid leukemia (AML) is an aggressive form of blood cancer that primarily affects older people and often has a poor prognosis despite improved therapies. In recent years, the targeted drug venetoclax has significantly improved treatment. In combination with other drugs, venetoclax often shows good therapeutic success in AML and will, at least in part, replace highly aggressive chemotherapy in the future. However, AML returns in nearly al…